These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35073650)

  • 1. [The prospects of DNA damage repair variants guiding platinum compounds in the treatment of triple negative breast cancer].
    Wang X; Yue J; Kang YK; Gao SL; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):68-72. PubMed ID: 35073650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
    Wang X; Yue J; Kang YK; Gao SL; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
    Telli M
    Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
    Jin J; Zhang W; Ji W; Yang F; Guan X
    Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Platinums in Triple-Negative Breast Cancer.
    Lynce F; Nunes R
    Curr Oncol Rep; 2021 Mar; 23(5):50. PubMed ID: 33754211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
    Stover DG; Winer EP
    Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer].
    Hong J; Chen XS; Wu JY; Huang O; Zhu L; He JR; Fang Q; Chen WG; Li YF; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):39-43. PubMed ID: 28104032
    [No Abstract]   [Full Text] [Related]  

  • 11. Platinum-based chemotherapy in triple-negative advanced breast cancer.
    Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
    Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
    Yang R; Shi YY; Han XH; Liu S
    Oncol Res Treat; 2021; 44(6):333-343. PubMed ID: 33975311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Opportunity and challenge of neoadjuvant treatment in triple negative breast cancer].
    Hao XP; Jiang ZF
    Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):101-103. PubMed ID: 33378800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
    Wang D; Feng J; Xu B
    Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
    [No Abstract]   [Full Text] [Related]  

  • 16. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
    Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How shall we treat locally advanced triple negative breast cancer?
    Luz P; Dias D; Fortuna A; Bretes L; Gosalbez B
    F1000Res; 2019; 8():1649. PubMed ID: 32802311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
    Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.